USA
FDA Final Guidance on Technical Specifications for Clinical Data
The U.S. Food and Drug Administration (FDA) released two final guidance documents intended to support pharmaceutical companies in submitting standardized clinical data. These guidances provide technical specifications for submitting general Clinical Outcome Assessment (COA) data and Patient-Reported Outcome (PRO) data collected from oncology clinical studies. The objective is to improve the consistency and quality of clinical data submissions to the FDA.
Addressing the Impact of Medical Misinformation
The Reagan-Udall Foundation recently issued a report addressing the growing challenge of medical misinformation and its impact on public confidence in science and regulatory authorities. The report highlights strategies the FDA can adopt to improve public communication, strengthen transparency, and enhance understanding of the agency’s role and the products it regulates.
Importance of Comprehensive Responses to FDA Form 483
Although companies are not legally required to submit written responses to an FDA Form 483, regulatory experts strongly recommend doing so. According to Rebecca Asente, a compliance officer within the FDA’s Office of Regulatory Affairs, companies should provide well-structured and comprehensive responses that clearly describe corrective and preventive actions addressing the cited deficiencies. Properly organized responses help facilitate regulatory review and communication following inspections.
Draft Guidance on Remote Regulatory Assessments for Drug Facilities
The FDA has issued draft guidance describing its approach to voluntary Remote Regulatory Assessments (RRAs). These assessments allow the agency to evaluate manufacturing facilities remotely, either in place of or as a supplement to on-site inspections. RRAs may involve reviewing records, conducting virtual meetings, or assessing facility operations through remote tools.
Communications on Unapproved Use of Approved Products is Focus of Draft Guidance
The FDA has issued a draft guidance intended to strike a balance between health care providers’ interest in scientific information on unapproved uses of approved/cleared medical products and mitigating the FDA’s interest in prohibiting use of a product for an unapproved indication.
Draft Guidance on Communications Regarding Unapproved Uses of Approved Products
The FDA released draft guidance clarifying how companies may share scientific information related to unapproved uses of approved or cleared medical products. The guidance aims to balance the need for healthcare professionals to access scientific information with the agency’s responsibility to prevent promotion of products for unapproved indications.
Guidance on Risk-Benefit Assessment in Drug Regulation
The FDA issued final guidance explaining how risk-benefit considerations are evaluated during both premarket and postmarket regulatory decisions related to New Drug Applications (NDAs) and Biologics License Applications (BLAs). The document provides insight into how the agency assesses safety and effectiveness when making regulatory determinations.
Clinical Trial Development for Diabetic Foot Infection Drugs
A new draft guidance outlines recommendations for the development of drugs intended to treat diabetic foot infections (DFI). The document provides advice on designing clinical trials, establishing development programs, and evaluating safety and effectiveness for these therapies.
Quality Considerations for Ophthalmic Drug Products
The FDA also released draft guidance addressing quality considerations for ophthalmic drug products. Topics covered include the assessment of impurities, evaluation of visible particulate matter, container closure system design, stability testing, and the evaluation of extractables and leachables. The guidance also discusses in vitro drug release and dissolution testing methods used for quality control.
FDA IT Modernization Strategy
The FDA’s IT modernization strategy for fiscal years 2024 through 2027 emphasizes improvements in data sharing, electronic submissions, and collaboration with industry stakeholders. The plan also highlights the responsible integration of artificial intelligence and machine learning technologies to support clinical research and regulatory review processes.
Updated MAPP for ANDA Assessment Practices
The FDA has updated its Manual of Policies and Procedures (MAPP) related to Abbreviated New Drug Application (ANDA) assessment practices. The revisions are intended to streamline the review process and reduce the number of review cycles required before approval.
EUROPE
Publication of the First Electronic Product Information (ePI)
European regulatory authorities, including the Heads of Medicines Agencies (HMA), the European Commission, and the European Medicines Agency (EMA), have published the first electronic product information (ePI) for selected human medicines. Product information typically includes the Summary of Product Characteristics (SmPC), labelling information, and the package leaflet. By introducing electronic formats, regulators aim to make product information more accessible, easily updated, and available to healthcare professionals and patients through digital platforms.
Update to CTIS Training Programme – Module 10
The European Medicines Agency updated Module 10 of its Clinical Trial Information System (CTIS) training materials. These resources are designed to improve public understanding of the CTIS platform and assist stakeholders in submitting, managing, and withdrawing Clinical Trial Applications (CTAs). The materials provide guidance on how the system functions and support stakeholders in navigating regulatory procedures.
EMA Advice on Submitting Type I Variations
The EMA has advised marketing authorization holders to submit Type IA and Type IAIN variation applications by 30 November 2023 to ensure their processing before the agency’s year-end closure. This timeline allows the agency to acknowledge submissions within the regulatory timeframe specified in Commission Regulation (EC) No 1234/2008. Submissions made after 1 December 2023 may not begin review until January 2024.
Discontinuation of Radioactivity Monitoring for Medicines from Japan
Following the withdrawal of Commission Implementing Regulation (EU) No 297/2011, European authorities have discontinued the requirement to monitor medicines manufactured in Japan for radioactive contamination related to the Fukushima nuclear accident in 2011. The EMA continues to cooperate with international regulators to monitor potential safety risks related to radiation exposure.
Revised Transparency Rules for the Clinical Trials Information System
The EMA introduced revised transparency rules governing the publication of clinical trial information submitted through the CTIS platform. The updated framework simplifies access to clinical trial data for stakeholders such as patients and healthcare professionals. A key change is the removal of the deferral mechanism that previously allowed sponsors to delay the publication of certain trial data for several years.
Fee Application Form for Human Products in Ireland
The Health Products Regulatory Authority (HPRA) published an updated fee application form for human medicinal products (FIN-F0018). The document includes application templates, fee codes, and applicable fees for different regulatory submission types.
ASIA
Singapore
WHO Recognition of HSA as a WHO-Listed Authority
Singapore’s Health Sciences Authority (HSA) has been recognized by the World Health Organization as a WHO-Listed Authority (WLA) for its medicines regulatory system. This recognition indicates that the agency operates at a highly advanced regulatory maturity level and maintains strong oversight to ensure the safety, efficacy, and quality of medicines available in Singapore. The assessment involved a detailed review of regulatory practices, scientific decision-making processes, and implementation consistency.
Pakistan
Draft Guideline for Storage and Destruction of Substandard and Recalled Therapeutic Goods
The Drug Regulatory Authority of Pakistan (DRAP) has released a draft guideline outlining procedures for managing substandard, falsified, or recalled therapeutic goods. The document provides guidance on identifying, storing, documenting, and safely destroying products that fail to meet quality standards or are otherwise recalled.
New eService for Pharmaceutical and Biological Product Registration
DRAP has introduced a new electronic service that enables online submission of regulatory data for the registration and marketing authorization of pharmaceutical and biological products. The platform supports submissions for locally manufactured, imported, and exported human drugs. This initiative is part of DRAP’s digital transformation strategy to improve regulatory efficiency and ensure product safety and quality.
China
NMPA Applies for Membership in PIC/S
China’s National Medical Products Administration (NMPA) has applied to join the Pharmaceutical Inspection Co-operation Scheme (PIC/S). In November 2023, PIC/S confirmed NMPA’s applicant status. Through this process, China aims to strengthen its pharmaceutical inspection system, enhance quality management standards, and align its regulatory practices with international best practices.
